Endo to Divest International Pharmaceuticals to Knight (1)

Endo agrees to divest its International Pharmaceuticals business, primarily operated by Paladin Pharma, to Knight Therapeutics for a total consideration of up to $99 million.

• Consideration consists of an upfront cash payment of $84 million and up to an additional $15 million in upon milestones
• At closing, Knight will pay an upfront payment of C$120 million in cash
• Transaction close is expected to occur in mid-2025
• RBC Capital Markets is financial adviser to Knight

To view the source of this information, click here and here

To contact the reporter on this story:
Lara Sanli in New York at lsanli@bloomberg.net

To ...